跳至主要内容
临床试验/IRCT20230618058519N1
IRCT20230618058519N1招募中3 期

Evaluating the clinical efficacy of adding Ivabradine to the standard treatment in reducing the frequency of premature atrial complexes (PAC) in ECG holter comparing to the standard treatment , in patients with symptomatic frequent premature atrial complexes (PAC)

Tehran heart center0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Patient in ages between 18-75 years.
  • PAC frequency in ECG holter be between 5-10 % (average of 8%).
  • Patients who have the ability to understand and sign the letter of satisfaction.

排除标准

  • Patient have the history of using Ivabradine during last 2 months.
  • Patients having cardiovascular disorders.
  • Patients having congenital long QT or QT>500 msec at the beginning of study.
  • using drugs with reducing heart rate effect, which have major interactions with Ivabradine.
  • Patients whom are pregnant or lactating or tending to become pregnant.
  • Patients suffering from advanced liver disease (class C of Child-Pugh score).
  • Patient having the history of using Ivabradine, whom has had discontinued Ivabradine because of adverse effects.
  • Patient having AF rhythm.

研究者

发起方
Tehran heart center

相似试验

Evaluating the efficacy of Ivabradine in reducing... | 临床试验